Pharmstandard led Cursor’s TOP-15 ranking for new marketing authorisations in 2024–2025 and secured a spot among the top five industry leaders based on the total number of International Non-proprietary Names (INNs).
The report provided by Cursor https://cursor-is.ru/ru/reports/TOP-50_otechestvenn_proizvoditelei_LS_2025.pdf reflects data on current marketing authorisations and marketing authorisations issued in accordance with the rules of the EAEU. The rating is based on information from the State Register of Medicines and The Cursor database. Drug Reference Book.
Ranking positions are determined by the number of international nonproprietary names (INNs) produced. If the number of INNs is equal, the manufacturer with the highest proportion of INNs included on the List of Vital and Essential Drugs (ZhNVLP) takes the top spot. The rating takes into account marketing authorisations valid and issued in accordance with the EAEU rules for the period from 2000 to 2025.
According to data provided by Cursor, Pharmstandard ranks first in the number of new MAs for the 2024–2025 period.
The company also ranks second in the number of INNs in liquid dosage forms, second in the number of INNs for inhalation administration, and third in the number of INNs in forms for topical and external use.
| Back | Print out |
